# A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

> **NCT04460820** · NA · COMPLETED · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Doxorubicin Hydrochloride Liposome Injection

## Key facts

- **NCT ID:** NCT04460820
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-04
- **Primary completion:** 2019-12-23
- **Final completion:** 2019-12-23
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04460820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04460820, "A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04460820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*